A population-based study of gefitinib in patients with non-small cell lung cancer

被引：0

作者：

Kenji Hayashibara

Hiroaki Satoh

Yoko Shinohara

Masaharu Inagaki

Takayuki Kaburagi

Toshio Hashimoto

Koichi Kurishima

Hiroichi Ishikawa

Hideo Ichimura

Takeshi Nawa

Yasunori Funayama

Takeshi Matsumura

Katsunori Kagohashi

Takeshi Endo

Kinya Furukawa

Koji Kishi

Masaaki Sumi

Koichi Kamiyama

Shigemi Ishikawa

机构：

[1] Ibaraki Higashi Hospital,Division of Respiratory Medicine, Institute of Clinical Medicine

[2] University of Tsukuba Hospital,undefined

[3] Tsuchiura Kyodo General Hospital and Regional Cancer Center,undefined

[4] Ibaraki Prefectural Central Hospital and Regional Cancer Center,undefined

[5] Mito Saiseikai Hospital,undefined

[6] Tsukuba Medical Center Hospital and Regional Cancer Center,undefined

[7] Hitachi General Hospital,undefined

[8] Tsukuba Gakuen General Hospital,undefined

[9] Ibaraki Seinan General Hospital,undefined

[10] Kasumigaura Medical Center Hospital,undefined

[11] Mito Medical Center Hospital,undefined

[12] Tokyo Medical University Kasumigaura Hospital,undefined

[13] Kensei General Hospital,undefined

[14] Tsukuba Kinen Hospital,undefined

来源：

Medical Oncology | 2009年 / 26卷

关键词：

Gefitinib; IRESSA; Non-small-cell lung cancer; Population-based study;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Survival data for non-small cell lung cancer is typically reported from clinical trials that include patients fit enough to meet treatment criteria. The denominator of all patients from which the gefitinib-treated population is derived has rarely been reported and the impact of gefitinib on population-based outcomes is difficult to measure. We have retrospectively reviewed data of 626 patients who received gefitinib in Ibaraki Prefecture (with a population of 3 million) in Japan from July 2002 until September 2007. Overall response rate was found to 30.8%, and the median survival time was 8.0 months (95% confidence interval: 7.0–9.0 months). Female gender, good PS, and adenocarcinoma were significantly associated with prolonged survival. Adverse events were generally mild and were mostly skin reactions and diarrhea. Our population-based study has generated similar results to those previously reported in published clinical trials, which had restrictive criteria for eligible patients.

引用

页码：222 / 227

页数：5

共 48 条

[1]

Molina JR(2006)Advances in chemotherapy of non-small cell lung cancer Chest 130 1211-9

[2]

Adjei AA(2003)A systematic overview of radiation therapy effects in non-small cell lung cancer Acta Oncol 42 493-515

[3]

Jett JR(2003)Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) J Clin Oncol 21 2237-46

[4]

Sirzén F(2006)Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients Lung Cancer 54 201-7

[5]

Kjellén E(2006)Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients J Thorac Oncol 1 520-5

[6]

Sörenson S(2007)Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer Cancer Sci 98 226-30

[7]

Cavallin-Ståhl E(1985)Long-term survival in small-cell carcinoma of the lung: a population experience J Clin Oncol 3 80-91

[8]

Fukuoka M(1997)The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group Br J Cancer 75 1534-42

[9]

Han SW(1988)Variation in survival of patients with lung cancer in Europe, 1985–1989 Eur J Cancer 34 2191-6

[10]

Chang GC(1988)Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study Ann Oncol 9 543-7

← 1 2 3 4 5 →